Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

被引：0

作者：

Zhang, Yi ^{[1
]}

Zhou, Hu ^{[2
]}

Suo, Shanshan ^{[1
]}

Zhuang, Junling ^{[3
]}

Yang, Linhua ^{[4
]}

He, Aili ^{[5
]}

Liu, Qingchi ^{[6
]}

Du, Xin ^{[7
]}

Gao, Sujun ^{[8
]}

Li, Yarong ^{[9
]}

Li, Yan ^{[10
]}

Chen, Yuqing ^{[11
]}

Wu, Wen ^{[12
]}

Zhu, Huanling ^{[13
]}

He, Guangsheng ^{[14
]}

Hong, Mei ^{[15
]}

Jiang, Qian ^{[16
]}

Jiang, Zhongxing ^{[17
]}

Jing, Hongmei ^{[18
]}

Wang, Jishi ^{[19
]}

Xu, Na ^{[20
]}

Yue, Lingling ^{[21
]}

Zheng, Cuiping ^{[22
]}

Zhou, Zeping ^{[23
]}

Jin, Chenghao ^{[24
]}

Li, Xin ^{[25
]}

Liu, Lin ^{[26
]}

Xu, Yajing ^{[27
]}

Wu, Dengshu ^{[28
]}

Zhang, Feng ^{[29
]}

Zhang, Jin ^{[30
]}

Xiao, Zhijian ^{[31
]}

Jin, Jie ^{[1
]}

机构：

[1] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Hematol, Hangzhou, Peoples R China

[2] Henan Prov Hematol Hosp, Dept Hematol, Zhengzhou, Henan, Peoples R China

[3] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Beijing, Peoples R China

[4] Second Hosp Shanxi Med Univ, Neurosurg, Taiyuan, Peoples R China

[5] Xi An Jiao Tong Univ, Dept Neurol, Affiliated Hosp 2, Xian, Peoples R China

[6] Hebei Med Univ, Hosp 1, Shijiazhuang, Peoples R China

[7] Southern Med Univ, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Hematol, Guangzhou, Peoples R China

[8] First Hosp Jilin Univ, Dept Hematol, Changchun, Peoples R China

[9] Second Hosp Jilin Univ, Dept Hematol & Oncol, Changchun, Peoples R China

[10] China Med Univ, Affiliated Hosp 1, Dept Hematopathol, Shenyang, Peoples R China

[11] Henan Prov Peoples Hosp, Dept Hematol, Zhengzhou, Peoples R China

[12] Shanghai Jiao Tong Univ, Shanghai Inst Hematol, Natl Res Ctr Translat Med Shanghai, State Key Lab Med Genom,Ruijin Hosp,Sch Med, Shanghai, Peoples R China

[13] Sichuan Univ, West China Hosp, Dept Hematol, Chengdu, Peoples R China

[14] Nanjing Med Univ, Key Lab Hematol, Jiangsu Prov Hosp, Collaborat Innovat Ctr Canc Personalize,Affiliated, Nanjing, Peoples R China

[15] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China

[16] Peking Univ, Inst Hematol, Natl Clin Res Ctr Hematol Dis, Peoples Hosp, Beijing, Peoples R China

[17] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China

[18] Peking Univ Third Hosp, Beijing, Peoples R China

[19] GuiZhou Med Univ, Dept Hematol, Affiliated Hosp, Guiyang City, Peoples R China

[20] Southern Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou, Peoples R China

[21] Lanzhou Univ Second Hosp, Dept Hematol & Oncol, Lanzhou, Peoples R China

[22] Wenzhou Cent Hosp, Dept Oncol 2, Wenzhou, Peoples R China

[23] Kunming Med Univ, Affiliated Hosp 2, Kunming, Peoples R China

[24] Jiangxi Prov Peoples Hosp, Nanchang, Peoples R China

[25] Cent South Univ, Third Xiangya Hosp, Dept Hematol, Changsha, Peoples R China

[26] Chongqing Med Univ, Affiliated Hosp 1, Dept Hematol, Chongqing, Peoples R China

[27] Cent South Univ, Xiangya Hosp, Changsha, Peoples R China

[28] Cent South Univ, Xiangya Hosp, Dept Hematol, Changsha, Peoples R China

[29] Bengbu Med Coll, Affiliated Hosp 1, Dept Hematol, Bengbu, Peoples R China

[30] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Hematol, Hangzhou, Peoples R China

[31] Chinese Acad Med Sci & Peking Union Med Coll, MDS & MPN Ctr, Inst Hematol & Blood Dis Hosp, Tianjin, Peoples R China

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-202790

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：3165 / 3166

页数：2

共 50 条

[1] A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS
Bozik, Michael E.
Mitsumoto, Hiroshi
Brooks, Benjamin R.
Rudnicki, Stacy A.
Moore, Dan H.
Zhang, Bing
Ludolph, Albert
Cudkowicz, Merit E.
Van den Berg, Leonard H.
Mather, James
Petzinger, Thomas, Jr.
Archibald, Donald
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2014, 15 (5-6) : 406 - 413
[2] Neutropenia and efficacy outcomes in patients with refractory mCRC: A post-hoc analysis of the phase III SUNLIGHT trial
Prager, G.
Tabernero, J.
Fakih, M.
Ciardiello, F.
Van Cutsem, E.
Roby, L.
Yao, W.
Choucair, E.
Taieb, J.
ANNALS OF ONCOLOGY, 2024, 35 : S18 - S19
[3] Guselkumab in Patients with Scalp Psoriasis: A post hoc Analysis of the VOYAGE 2 Phase III Randomized Clinical Trial
Sonkoly, Enikoe
Maul, Julia-Tatjana
Megna, Matteo
Gorecki, Patricia
Crombag, Edmee
Buyze, Jozefien
Savage, Laura
ACTA DERMATO-VENEREOLOGICA, 2024, 104
[4] An analysis of feasibility of robotic colectomy: post hoc analysis of a phase III randomised controlled trial
Fleming, Christina A.
Celarier, Soline
Fernandez, Benjamin
Cauvin, Thomas
Celerier, Bertrand
Denost, Quentin
JOURNAL OF ROBOTIC SURGERY, 2023, 17 (03) : 1057 - 1063
[5] An analysis of feasibility of robotic colectomy: post hoc analysis of a phase III randomised controlled trial
Christina A. Fleming
Soline Celarier
Benjamin Fernandez
Thomas Cauvin
Bertrand Célérier
Quentin Denost
Journal of Robotic Surgery, 2023, 17 : 1057 - 1063
[6] Per-Treatment Post Hoc Analysis of Clinical Trial Outcomes With Tolvaptan in ADPKD
Mallett, Andrew J.
Perrone, Ronald D.
Rangan, Gopala
Hawley, Carmel
El-Damanawi, Ragada
Hiemstra, Thomas F.
Arellano, Carolina Townsend
Lee, Jennifer
Torres, Vicente E.
KIDNEY INTERNATIONAL REPORTS, 2021, 6 (04): : 1032 - 1040
[7] Testosterone nadir and clinical outcomes in patients with advanced prostate cancer: Post hoc analysis of triptorelin pamoate Phase III studies
Klotz, Laurence
Tat, Tri
BJUI COMPASS, 2024, 5 (03): : 392 - 402
[8] Outcomes and management of invasive procedures in participants with hemophilia A post gene therapy: a post hoc analysis of the GENEr8-1 phase III trial
Quon, Doris V.
Wang, Jiaan-Der
Wang, Michael
Pepperell, Dominic
Park, Young-Shil
Kenet, Gili
Mahlangu, Johnny
Khoo, Teh-Liane
Robinson, Tara M.
Chavele, Konstantia-Maria
Pipe, Steven W.
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2024, 15
[9] Post hoc subgroup analysis and the truth of a clinical trial
Adams, KF
AMERICAN HEART JOURNAL, 1998, 136 (05) : 753 - 758
[10] Clinical implications and outcomes of the ORION Phase III trials
Brandts, Julia
Ray, Kausik K.
FUTURE CARDIOLOGY, 2020, 17 (05) : 769 - 777

← 1 2 3 4 5 →